查和活体验证关键基因参与骨髓损伤在阿尔茨海默氏病的活体验证
Hai-Tao Li1,2, Ji-Wei Zhang3, Bo-Wen Li1,4
1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
Molecular neurobiology
|November 29, 2025
概括
骨髓损伤加剧了阿尔茨海默病 (AD) 的认知衰退. 这项研究发现,AD小鼠的8个关键基因被下调,影响髓,突触和关键的信号通路,为AD病原体提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 骨髓损伤是阿尔茨海默病 (AD) 认知能力下降的重要因素.
- 了解AD中髓损伤的遗传基础对于开发向疗法至关重要.
研究的目的:
- 为了确定与阿尔茨海默病中髓膜损伤相关的关键基因.
- 在AD小鼠模型中,研究潜在的髓和突触损伤的分子机制.
主要方法:
- 对GSE118553数据集的分析,以确定差异表达的基因.
- 在阿尔茨海默病小鼠模型中验证基因表达.
- 传输电子显微镜和分子生物学技术评估髓,突触损伤和信号通路蛋白质.
主要成果:
- 与髓膜损伤相关的11个已识别的关键基因中有8个在AD小鼠中被下调.
- 在AD小鼠中,表现出粉样β沉积,陶过,以及对髓和突触的损伤.
- 观察到IRS-1/PI3K/Akt/GSK3β信号通路蛋白和葡萄糖载体 (GLUT1/3) 的异常表达.
结论:
- 特定基因的下调有助于阿尔茨海默病中髓和突触损伤.
- IRS-1/PI3K/Akt/GSK3β信号通路和葡萄糖代谢与AD相关的髓病理有关.
- 这项研究为探索AD骨髓膜损伤中的基因调节机制提供了基础.
更多相关视频
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
449
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.3K
相关概念视频
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:22Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736